Corient Private Wealth LLC Sells 3,876 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Corient Private Wealth LLC decreased its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 32.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,082 shares of the medical research company’s stock after selling 3,876 shares during the quarter. Corient Private Wealth LLC’s holdings in Charles River Laboratories International were worth $1,492,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Versant Capital Management Inc raised its position in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after buying an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. grew its stake in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares in the last quarter. Tortoise Investment Management LLC raised its holdings in shares of Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 115 shares during the last quarter. ORG Wealth Partners LLC bought a new stake in shares of Charles River Laboratories International in the fourth quarter worth $56,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in Charles River Laboratories International during the third quarter worth $59,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Charles River Laboratories International news, CEO James C. Foster purchased 6,075 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. The Goldman Sachs Group cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their price target for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. Barclays dropped their target price on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 18th. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target for the company in a research report on Monday, March 3rd. Morgan Stanley lowered their price target on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Finally, Robert W. Baird cut their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the stock. According to MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and an average target price of $189.77.

Charles River Laboratories International Price Performance

Shares of CRL opened at $161.57 on Wednesday. The company’s 50-day moving average is $165.32 and its 200-day moving average is $183.30. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The firm has a market capitalization of $8.26 billion, a PE ratio of 1,077.13, a PEG ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a fifty-two week low of $150.79 and a fifty-two week high of $273.32.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same period in the prior year, the firm earned $2.46 EPS. The business’s revenue was down 1.1% on a year-over-year basis. Equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).